Patents by Inventor Oshrat Propheta-Meiran

Oshrat Propheta-Meiran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945875
    Abstract: Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: April 2, 2024
    Assignee: ImmuneWalk Therapeutics, Inc.
    Inventors: Itzhak Mendel, Oshrat Propheta-Meiran, Yaniv Salem, Anat Shoham, Niva Yacov, Eyal Breitbart
  • Publication number: 20210095044
    Abstract: Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.
    Type: Application
    Filed: October 13, 2020
    Publication date: April 1, 2021
    Inventors: ITZHAK MENDEL, Oshrat PROPHETA-MEIRAN, Yaniv SALEM, Anat SHOHAM, Niva YACOV, Eyal BREITBART
  • Publication number: 20210077622
    Abstract: Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 and pharmaceutical compositions containing MOSPD2 inhibitors.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: ITZHAK MENDEL, Oshrat Propheta-Meiran, Yaniv Salem, Anat Shoham, Eyal Breitbart
  • Publication number: 20190040150
    Abstract: Disclosed herein are methods of treating, reducing the incidence of, or preventing one or more activities in or of a cancer cell, methods of treating, reducing the incidence of, or preventing migration or metastasis of a cancer cell, methods of treating, reducing the incidence of, or preventing a cancer by reducing tumor associated macrophages (TAMs) or their migration, and methods of treating, reducing the incidence of, or preventing a cancer (including metastatic cancer), for example, with an inhibitor of Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 (e.g., anti-MOSPD2 antibodies or antigen binding fragments thereof) and pharmaceutical compositions containing MOSPD2 inhibitors. Also disclosed are methods for the prediction, diagnosis, or prognosis of cancer, cancer metastasis, tumor progression, or tumor invasiveness in a subject.
    Type: Application
    Filed: July 29, 2016
    Publication date: February 7, 2019
    Inventors: Itzhak Mendel, Oshrat PROPHETA-MEIRAN, Yaniv SALEM, Anat SHOHAM, Niva YACOV, Eyal BREITBART
  • Publication number: 20180214543
    Abstract: Disclosed herein are methods of treating, preventing, or reducing the incidence of an inflammatory disease or disorder and methods of inhibiting, preventing, or reducing the incidence of one or more activities in a cell with an inhibitor of a Motile Sperm Domain containing Protein 2 (MOSPD2). Also disclosed are inhibitors of MOSPD2 and pharmaceutical compositions containing MOSPD2 inhibitors.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 2, 2018
    Inventors: Itzhak Mendel, Oshrat PROPHETA-MEIRAN, Yaniv SALEM, Anat SHOHAM, Eyal BREITBART
  • Publication number: 20150320773
    Abstract: Disclosed herein are methods of treating an inflammatory disease or disorder, as well as pharmaceutical compositions and kits useful for treating an inflammatory disease or disorder. The methods, compositions and kits utilize at least one agent, the at least one agent being capable of exhibiting at least two activities selected from the group consisting of: a) inhibiting CD 14 activity and/or a signaling pathway associated with CD 14 activity; b) inhibiting TLR2 activity and/or a signaling pathway associated with TLR2 activity; and c) inhibiting monocyte chemotaxis.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 12, 2015
    Inventors: ITZHAK MENDEL, Erez Feige, Niva Yacov, Oshrat Propheta-Meiran, Eyal Breitbart, Yaniv Salem